G. Lyman, Risks and Consequences of Chemotherapy-Induced Neutropenia, Clinical Cornerstone, vol.8, issue.5, pp.12-18, 2006.
DOI : 10.1016/S1098-3597(06)80054-2

M. Stokes, C. Muehlenbein, M. Marciniak, D. Faries, S. Motabar et al., Neutropenia-Related Costs in Patients Treated with First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer, Journal of Managed Care Pharmacy, vol.15, issue.8, pp.15669-682, 2009.
DOI : 10.18553/jmcp.2009.15.8.669

J. Crawford, D. Dale, and G. Lyman, Chemotherapy-induced neutropenia, Cancer, vol.112, issue.2, pp.228-237, 2004.
DOI : 10.1002/cncr.11882

J. De-naurois, I. Novitzky-basso, M. Gill, F. Marti, M. Cullen et al., Management of febrile neutropenia: ESMO Clinical Practice Guidelines, Annals of Oncology, vol.21, issue.Supplement 5, pp.252-256, 2010.
DOI : 10.1093/annonc/mdq196

M. Aapro, J. Crawford, and D. Kamioner, Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer, pp.529-541, 2010.

M. Aapro, J. Bohlius, D. Cameron, D. Lago, L. Donnelly et al., update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours, p.2010

J. Crawford, J. Armitage, L. Balducci, C. Bennett, D. Blayney et al., Myeloid Growth Factors, J Natl Compr Canc Netw, vol.2, issue.7, pp.64-83, 2009.
DOI : 10.1182/blood-2003-06-2094

A. Jakobsen, A. Berglund, B. Glimelius, J. Frodin, F. Hansen et al., Dose-effect Relationship of Bolus 5-Fluorouracil in the Treatment of Advanced Colorectal Cancer, Acta Oncologica, vol.41, issue.6, pp.41525-531, 2002.
DOI : 10.1080/02841860214959

D. Radosavljevic, I. Golubicic, D. Gavrilovic, I. Kezic, and S. Jelic, Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?, J BUON, vol.14, issue.2, pp.203-209, 2009.

R. Pettengell, M. Schwenkglenks, R. Leonard, A. Bosly, R. Paridaens et al., Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study, Supportive Care in Cancer, vol.6, issue.23, pp.161299-1309, 2008.
DOI : 10.1007/s00520-008-0430-4

C. Nagel, F. Backes, E. Hade, D. Cohn, E. Eisenhauer et al., Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer, Gynecologic Oncology, vol.124, issue.2, pp.221-224, 2012.
DOI : 10.1016/j.ygyno.2011.10.003

A. Brunetto, C. Carden, J. Myerson, A. Faria, S. Ashley et al., Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy, Journal of Thoracic Oncology, vol.5, issue.9, pp.1397-1403, 2010.
DOI : 10.1097/JTO.0b013e3181eba7f9

D. Dale, Colony-Stimulating Factors for the Management of Neutropenia in Cancer Patients, Drugs, vol.15, issue.Supplement 1, pp.1-15, 2002.
DOI : 10.2165/00003495-200262001-00001

J. Crawford, H. Ozer, R. Stoller, D. Johnson, G. Lyman et al., Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with smallcell lung cancer, N Engl J Med, issue.3, pp.325164-170, 1991.

N. Kuderer, D. Dale, J. Crawford, L. Cosler, and G. Lyman, Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients, Cancer, vol.85, issue.10, pp.2258-2266, 2006.
DOI : 10.1002/cncr.21847

DOI : 10.1016/S0140-6736(89)91552-3

V. Trillet-lenoir, J. Green, C. Manegold, V. Pawel, J. Gatzemeier et al., Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy, European Journal of Cancer, vol.29, issue.3, pp.29-319, 1993.
DOI : 10.1016/0959-8049(93)90376-Q

N. Kuderer, D. Dale, J. Crawford, and G. Lyman, Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review, Journal of Clinical Oncology, vol.25, issue.21, pp.253158-3167, 2007.
DOI : 10.1200/JCO.2006.08.8823

G. Lyman, N. Kuderer, and B. Djulbegovic, Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis, The American Journal of Medicine, vol.112, issue.5, pp.406-411, 2002.
DOI : 10.1016/S0002-9343(02)01036-7

A. Potosky, J. Malin, B. Kim, E. Chrischilles, S. Makgoeng et al., Use of Colony-Stimulating Factors With Chemotherapy: Opportunities for Cost Savings and Improved Outcomes, JNCI Journal of the National Cancer Institute, vol.103, issue.12, pp.979-982, 2011.
DOI : 10.1093/jnci/djr152

L. Sung, P. Nathan, S. Alibhai, G. Tomlinson, and J. Beyene, Meta-analysis: Effect of Prophylactic Hematopoietic Colony-Stimulating Factors on Mortality and Outcomes of Infection, Annals of Internal Medicine, vol.147, issue.6, pp.400-411, 2007.
DOI : 10.7326/0003-4819-147-6-200709180-00010

D. Hershman, E. Wilde, J. Wright, D. Buono, K. Kalinsky et al., PD06-04: Uptake and Economic Impact of First-Cycle Colony Stimulating Factor Use during the Adjuvant Treatment of Breast Cancer., Cancer Research, vol.71, issue.24 Supplement, pp.30806-812
DOI : 10.1158/0008-5472.SABCS11-PD06-04

L. Schnipper, T. Smith, D. Raghavan, D. Blayney, P. Ganz et al., American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology, Journal of Clinical Oncology, vol.30, issue.14, pp.301715-1724
DOI : 10.1200/JCO.2012.42.8375

T. Smith, J. Khatcheressian, G. Lyman, H. Ozer, J. Armitage et al., update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline, J Clin Oncol, issue.19, pp.243187-3205, 2006.

H. Mellstedt, D. Niederwieser, and H. Ludwig, The challenge of biosimilars, Annals of Oncology, vol.19, issue.3, pp.411-419, 2008.
DOI : 10.1093/annonc/mdm345

H. Schellekens, Follow-on biologics: challenges of the 'next generation', Nephrology Dialysis Transplantation, vol.20, issue.suppl_4, pp.31-36, 2005.
DOI : 10.1093/ndt/gfh1085

A. Skrlin, I. Radic, M. Vuletic, D. Schwinke, D. Runac et al., Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim, Biologicals, vol.38, issue.5, pp.557-566, 2010.
DOI : 10.1016/j.biologicals.2010.05.002

C. Waller, M. Bronchud, S. Mair, and R. Challand, Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial, Annals of Hematology, vol.19, issue.Suppl 1, pp.971-978, 2010.
DOI : 10.1007/s00277-010-0973-6

URL : https://hal.archives-ouvertes.fr/hal-00549425

C. Waller, M. Bronchud, S. Mair, and R. Challand, Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial, Annals of Hematology, vol.23, issue.Suppl 1, pp.927-933, 2010.
DOI : 10.1007/s00277-010-0961-x

URL : https://hal.archives-ouvertes.fr/hal-00535133

C. Waller, V. Semiglazov, S. Tjulandin, D. Bentsion, S. Chan et al., A Phase III Randomized Equivalence Study of Biosimilar Filgrastim versus Amgen Filgrastim in Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer, Onkologie, vol.33, issue.10, pp.33504-511, 2010.
DOI : 10.1159/000319693

P. Gravel, A. Naik, L. Cotonnec, and J. , Biosimilar rhG-CSFs: how similar are they?, Targeted Oncology, vol.8, issue.suppl 2, pp.3-16
DOI : 10.1007/s11523-011-0187-4

S. Roger and A. Mikhail, Biosimilars: opportunity or cause for concern, J Pharm Pharm Sci, vol.10, issue.3, pp.405-410, 2007.

H. Schellekens, Biosimilar therapeutics-what do we need to consider? NDT Plus, pp.27-36, 2009.

B. Shaw, D. Confer, W. Hwang, D. Pamphilon, and M. Pulsipher, Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association, Haematologica, vol.96, issue.7, pp.96942-947, 2011.
DOI : 10.3324/haematol.2011.045740

H. Inc, Nivestim summary of product characteristics, 2010.

S. Fruehauf, R. Haas, C. Conradt, S. Murea, B. Witt et al., Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy, Blood, vol.85, issue.9, pp.2619-2626, 1995.

S. Fruehauf, K. Schmitt, M. Veldwijk, J. Topaly, A. Benner et al., Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients, British Journal of Haematology, vol.85, issue.3, pp.786-794, 1999.
DOI : 10.1046/j.1365-2141.1996.448987.x

C. Straka, F. Oduncu, A. Hinke, H. Einsele, E. Drexler et al., Responsiveness to G-CSF before leukopenia predicts defense to infection in high-dose chemotherapy recipients, Blood, vol.104, issue.7, pp.1989-1994, 2004.
DOI : 10.1182/blood-2004-02-0628

B. Burnett and R. Krle?a, Stability of Hospira filgrastim following changes to thermal and photic storage conditions, Eur J Hosp Pharm Sci, vol.17, issue.5, pp.50-57, 2011.

N. Institute and H. Research, Research Capability Programme: background, vision, overview and glossary, 2008.

V. Morrison, M. Wong, D. Hershman, L. Campos, B. Ding et al., Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices, Journal of Managed Care Pharmacy, vol.13, issue.4, pp.337-348, 2007.
DOI : 10.18553/jmcp.2007.13.4.337

. Kamioner, Study design: two long-term observational studies of the biosimilar filgrastim Nivestim??? (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia, BMC Cancer, vol.13, issue.4, p.547, 2013.
DOI : 10.1182/blood-2004-02-0628

URL : https://hal.archives-ouvertes.fr/hal-01128970